Thonzonium (bromide)

Thonzonium bromide is an antibacterial agent that is structurally similar to Farnesol (HY-Y0248A) . Thonzonium bromide is also a monocationic surface-active agent, which inhibits RANKL-induced osteoclast formation and bone resorption in vitro and prevents LPS-induced bone loss in vivo. Thonzonium bromide inhibits proton transport in a dose-dependent manner (EC50=69 μM) [1][2][3].

Product Specifications

CAS Number

[553-08-2]

UNSPSC

12352005

Hazard Statement

H302+H312+H332, H315, H318, H335

Target

Bacterial; Proton Pump

Type

Reference compound

Related Pathways

Anti-infection; Membrane Transporter/Ion Channel

Applications

COVID-19-immunoregulation

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/Thonzonium-bromide.html

Purity

99.86

Solubility

DMSO : ≥ 30 mg/mL|H2O : 100 mg/mL (ultrasonic)

Smiles

CCCCCCCCCCCCCCCC[N+](C)(CCN(CC1=CC=C(OC)C=C1)C2=NC=CC=N2)C.[Br-]

Molecular Formula

C32H55BrN4O

Molecular Weight

591.71

Precautions

H302+H312+H332, H315, H318, H335

References & Citations

[1]Zhu X, et al. Thonzonium bromide inhibits RANKL-induced osteoclast formation and bone resorption in vitro and prevents LPS-induced bone loss in vivo. Biochem Pharmacol. 2016;104:118-130.|[2]Chan CY, et al. Inhibitors of V-ATPase proton transport reveal uncoupling functions of tether linking cytosolic and membrane domains of V0 subunit a (Vph1p) . J Biol Chem. 2012;287 (13) :10236-10250.|[3]Sims KR, et al. Enhanced design and formulation of nanoparticles for anti-biofilm drug delivery. Nanoscale. 2018;11 (1) :219-236.